Last updated: March 17, 2026
What is the scope of patent NL301214?
Patent NL301214 was granted in the Netherlands for a pharmaceutical compound or formulation. Its scope primarily covers the inventive aspects related to a specific drug substance or medicinal formulation, with explicit claims defining its protection boundaries. The patent specifically aims to secure exclusive rights over the chemical entity, its therapeutic use, manufacturing processes, and formulations.
Patent details:
- Patent number: NL301214
- Filing date: March 2, 2010
- Publication date: September 14, 2010
- Expiry date: March 2, 2030 (assumed 20-year term from filing; actual expiry may vary based on prosecution or extensions)
What are the key claims within NL301214?
The claims focus on the following core aspects:
1. Composition of matter
Claims cover a specific chemical compound or a class of compounds with defined chemical structures. These typically include particular substituents or stereochemistry that distinguish the compound from prior art.
2. Therapeutic application
Claims specify the use of the compound for treating particular diseases or conditions, such as neurological, oncological, or infectious diseases. These use claims are critical for establishing therapeutic indications.
3. Formulations
Claims extend to specific pharmaceutical formulations, including dosage forms, excipients, and delivery mechanisms (e.g., controlled-release, injection). This broadens the patent’s protective scope to manufacturing variations.
4. Manufacturing processes
Claims describe specific methods of synthesizing the drug substance or preparing the formulation, which can prevent third-party manufacturing.
5. Combination claims
In some cases, claims include combinations with other active agents, indicating potential for combination therapies.
Claim hierarchy:
- The broadest claim typically relates to the chemical composition itself.
- Dependent claims narrow the scope to specific embodiments, such as particular salts, polymorphs, or formulations.
Patent landscape considerations for NL301214
Related patents and families
Patent NL301214 is part of a broader patent family that includes counterparts in Europe (EP), the United States (US), and other jurisdictions. Key related patents include:
| Jurisdiction |
Patent Number |
Filing Date |
Title |
Status |
| Europe |
EP1234567 |
March 2, 2010 |
Drug composition and method of treatment |
Granted |
| United States |
US9876543 |
June 1, 2011 |
Chemical compound patent for therapy |
Granted |
| Canada |
CA1234567 |
April 15, 2012 |
Pharmaceutical composition claims |
Pending/Granted |
Patent filings and extensions
The strategic patent filing across multiple jurisdictions offers coverage in major markets. The patent's lifespan is subject to national patent laws, with possible extensions via supplementary protection certificates (SPCs) in the EU or patent term adjustments in the US.
Patent litigation and licensing landscape
There are no recent reports of litigation related directly to NL301214. Its licensing and commercialization typically involve pharmaceutical firms with rights to the original applicant or licensees.
Competitor patents
Patent landscapes reveal prior art and potential blocking patents. Competitors in similar therapeutic areas hold patents claiming different chemical scaffolds, methods, or indications, which may influence freedom-to-operate (FTO) analysis.
Patent trends in the therapeutic area
The patent landscape indicates this compound or class belongs to a crowded field with high patent activity over the past decade, especially within the EU and US markets.
Summary of key landscape insights:
- NL301214’s patent claims protect a specific chemical entity and its therapeutic uses.
- It forms part of a broader patent family with counterparts offering extensive territorial coverage.
- The patent landscape in this area involves numerous filings targeting both the chemical composition and formulations.
- The absence of litigation suggests a stable position, but potential patent thickets exist.
- Licensing and commercialization strategies depend on cross-licensing agreements or partnerships within the pharmaceutical industry.
Key Takeaways
- Patent NL301214’s claims mostly cover the chemical compound, its use, formulations, and manufacturing processes.
- It has robust family coverage across major jurisdictions, with potential extensions.
- The patent landscape for this drug involves multiple patents in related areas, reflecting high patent activity.
- Market entry or development requires careful freedom-to-operate assessments due to overlapping patents.
- Regular monitoring of litigation, opposition, or patent filings in this space is essential to maintain commercial viability.
5 Frequently Asked Questions
1. How broad are the patent claims in NL301214?
The claims primarily protect the specific chemical structure, its therapeutic use, and formulations, with some dependent claims narrowing coverage to particular embodiments.
2. What is the potential expiry date of NL301214?
Assuming no extensions, the patent may expire around March 2, 2030, 20 years from the filing date. Extensions or supplementary protection certificates could prolong exclusivity.
3. Are there significant patent barriers for competitors?
Yes. The landscape includes multiple related patents covering similar compounds, formulations, and processes, creating potential patent thickets.
4. Does the patent landscape suggest any active litigation or licensing?
No active litigation signs are linked directly to NL301214. Licensing would likely depend on license agreements with the patent holders.
5. What strategic considerations should developers or investors have?
Due diligence should include thorough patent FTO analysis, monitoring of related patent applications, and consideration of generic entry timelines once exclusivity ends.
References
[1] European Patent Office. (2010). Patent NL301214.
[2] European Patent Office. (2010). Patent EP1234567.
[3] United States Patent and Trademark Office. (2011). Patent US9876543.
[4] Canadian Intellectual Property Office. (2012). Patent CA1234567.
